Cytopia begins Phase II

By Dylan Bushell-Embling
Thursday, 04 September, 2008

Cytopia [ASX: CYT] has commenced enrolment for its Phase 1b/II study of CYT997 for brain cancer.

CYT997 is a vascular disrupting agent being tested in patients with the aggressive brain cancer glioblastoma multiforme.

Around 30 patients will be involved in the study, which will be conducted at a number of clinical centres in Australia and overseas. CYT997 will be used in combination with two other marketed anticancer agents.

Glioblastomas often resurface even after surgical resection or radiation therapy, but are highly vascular and dependent on their own abnormal blood supply for growth. CYT997 is aimed at disrupting this supply.

Related News

RSV immunisation program for babies slashes hospital stays

An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...

A targeted treatment option for psoriasis

New research from MedUni Vienna paves the way for the development of a therapy that not only...

Maternal cannabis use puts kids at risk of behavioural problems

Children exposed to their mother's cannabis use during pregnancy and after birth are three...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd